Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma

BACKGROUND: Sintilimab plus chemotherapy (SIDCHM) is more effective than placebo plus chemotherapy (PLCHM) for advanced or metastatic esophageal squamous cell carcinoma (ESCC). However, considering the high cost of sintilimab, this study evaluated the cost-effectiveness of SIDCHM in comparison with...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Maojin, Huang, Yufan, Cai, Zhongjie, Wu, Qingfeng, Zhu, Wei, He, Ying, Chen, Ruijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773135/
https://www.ncbi.nlm.nih.gov/pubmed/36568254
http://dx.doi.org/10.3389/fonc.2022.986762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773135/
https://www.ncbi.nlm.nih.gov/pubmed/36568254
http://dx.doi.org/10.3389/fonc.2022.986762

Ejemplares similares